
Coromandel Inter Q4 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Specialty Nutrients (SND) expected to grow healthily by over 10-15%, with Rs. 600 Cr current turnover and plans to double sulfur production capacity (Page 11, 15).
- Nano DAP product anticipated to see significant growth; potential to replace 20-25% of imported DAP over 3-4 years; commercial sales started recently with encouraging market response (Page 9, 10, 17, 18).
- Retail business expanding rapidly, planning to open around 100 new stores in FY '25, targeting ~850 stores, including new markets like Tamil Nadu; achieved Rs. 1,700 Cr revenue previously (Page 10).
- Crop Protection Chemicals (CPC) registering strong 20% volume growth; margin pressures expected to ease with new products and operational efficiencies (Page 4, 15).
- Mining volume from Senegal expected to increase to 2.5-3 lakh tons aiding backward integration and operating leverage (Page 15).
- Specialty Chemicals segment progressing; last year Rs. 50 Cr revenue with growth expected as capex and integration come online by FY '26-FY '27 (Page 14).
- Drone business (Dhaksha) with Rs. 250 Cr order book for H1, potential for scaling revenues in FY '26-FY '27 (Page 8).
See what Coromandel Inter management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The company currently holds a strong cash balance of over Rs. 3,000 Cr (cash and investments combined).
- There is no mention of any immediate plans for new fundraising through debt or equity in the provided pages.
- Cash is primarily intended to fund ongoing and planned capital expenditure programs, organic growth, and potential inorganic expansion.
- The company is open to capital for further expansion and new opportunities, including specialty chemicals and CDMO, which may require future capex.
- For now, the company appears to be focusing on utilizing existing cash reserves for capex and growth rather than raising new funds through debt or equity.
See what Coromandel Inter management said on order book — free account, 30 seconds.
Capex plans
Yes- FY '25 capex estimated at Rs. 1,200 Cr to Rs. 1,500 Cr across multiple businesses.
- Major capex includes new Sulphuric Acid (SA) and Phosphoric Acid (PA) plants at Kakinada expected by FY '27.
- Setting up multipurpose plants (MPPs) for crop protection chemicals at Ankleshwar and Dahej; expected 18-20 months for commissioning.
- Debottlenecking granulation capacity by 3.5 lakh tons at Kakinada and Vizag.
- Nano DAP facility commissioning pending government approvals.
- Expanding retail stores by 100+ in FY '25, including new geographies like Tamil Nadu.
- Investment in specialty chemicals, including fluorination chemistries and leveraging CPC plant assets.
- Ongoing R&D and capacity build-up for Dhaksha drones; order book approx. Rs. 250 Cr.
- Open to inorganic growth opportunities and capex for future expansions in specialty chemicals and CDMO segments.
Track Coromandel Inter — get its next earnings analysis in your feed
How does Coromandel Inter rank vs peers in Fertilizers & Agrochemicals?
Pro featureHow does Coromandel Inter rank in Fertilizers & Agrochemicals?
Compare Coromandel Inter against every Fertilizers & Agrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Coromandel Inter's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Madhya Bharat Agro Products (Q2 FY27)
Q2 FY27 Revenue: ₹715 crore, up 59% YoY (Page 12, Chairman’s Quote) . Key investor presentation takeaways from Madhya Bharat Agro Products Ltd's Q2 FY27 investo
- Dhansa Labs (Q2 FY27)
1,864 crores during H1 FY27. Key results statement takeaways from Dhansa Labs Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Aristo Bio-Tech (Q2 FY27)
1,168.88 lakh, approximate operating margin is about 5.9% for the quarter. Key results statement takeaways from Aristo Bio-Tech & Lifescience Ltd's Q2 FY27 resu
- Krishana Phoschem (Q2 FY27)
Q2 FY27 Revenue: ₹703 crore, a 16% year-on-year (YoY) increase (Page 11). Key investor presentation takeaways from Krishana Phoschem Ltd's Q2 FY27 investor pres